Furthermore, menin inhibition may also restore normal HOXA/MEIS1 expression in mutated NPM1 and NUP98-r AML and thus have therapeutic implications in up to one third of pediatric AML patients, of whom a significant proportion have high-risk disease incurable with current treatment modalities. This evidence concerns the gene NPM1 and acute myeloid leukemia.